Sarcomas

Treatment with pembrolizumab (Keytruda) led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

The FDA has placed a partial clinical hold on a planned pivotal trial examining an investigational T-cell therapy in patients with myxoid round cell liposarcoma.

Andrew S. Brohl, MD, discusses some of the recent findings of genomic studies of sarcomas.

Researchers are focusing genomic sequencing studies on many different types of sarcomas to emphasize the significant heterogeneity and the unique molecular mechanisms underlying the development of these cancers.

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Treatment with aldoxorubicin failed to improve progression-free survival compared with investigator's choice of therapy for patients with advanced soft tissue sarcoma.

Noah Federman, MD, discusses challenges with treating pediatric patients and adolescent and young adults with sarcomas and ongoing efforts to overcome these obstacles.

Brian A. Van Tine, MD, PhD, discusses ongoing research in sarcomas, as well as provides insight on the impact existing drugs are making on the treatment landscape and what community oncologists need to know about this ever-changing field.